Pharmacokinetic Study of Cabotegravir Long-acting in Healthy Adult Volunteers

NCT02478463 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

19

Enrollment

INDUSTRY

Sponsor class

Conditions

Infection, Human Immunodeficiency Virus
HIV Infections

Interventions

DRUG: Cabotegravir tablet 30 mg once daily for 28 days.
DRUG: Cabotegravir injection 3 mL (200 mg/mL) IM given once on Day 1.

Sponsor

ViiV Healthcare